{"id":"pa21","safety":{"commonSideEffects":[{"rate":null,"effect":"Genital mycotic infections"},{"rate":null,"effect":"Urinary tract infections"},{"rate":null,"effect":"Polyuria"}]},"_chembl":{"chemblId":"CHEMBL174983","moleculeType":"Small molecule","molecularWeight":"250.28"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PA21 works by inhibiting SGLT2, a transporter protein in the kidney's proximal tubule that normally reabsorbs filtered glucose back into the bloodstream. By blocking this reabsorption, the drug increases urinary glucose excretion, thereby lowering blood glucose levels independent of insulin secretion. This mechanism also provides cardiovascular and renal protective benefits beyond glycemic control.","oneSentence":"PA21 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:25:13.979Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03644264","phase":"PHASE3","title":"PA21 Safety and Efficacy in Adult Chinese Subjects","status":"COMPLETED","sponsor":"Vifor Fresenius Medical Care Renal Pharma","startDate":"2018-08-31","conditions":"Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia","enrollment":286},{"nctId":"NCT02687594","phase":"","title":"Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis (HD) or Peritoneal Dialysis (PD)","status":"COMPLETED","sponsor":"Vifor Fresenius Medical Care Renal Pharma","startDate":"2016-04-06","conditions":"Hyperphosphatemia","enrollment":1400},{"nctId":"NCT02688764","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia","status":"TERMINATED","sponsor":"Vifor Fresenius Medical Care Renal Pharma","startDate":"2016-05-26","conditions":"Hyperphosphatemia","enrollment":85},{"nctId":"NCT03010072","phase":"PHASE2","title":"The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum","status":"COMPLETED","sponsor":"Prim. Priv. Doz. Dr. Daniel Cejka","startDate":"2017-06-09","conditions":"Endstage Renal Disease","enrollment":40},{"nctId":"NCT01850602","phase":"PHASE3","title":"A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2013-04-23","conditions":"Hemodialysis, Hyperphosphatemia","enrollment":213},{"nctId":"NCT01833494","phase":"PHASE3","title":"A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2013-03-18","conditions":"Hemodialysis Patients With Hyperphosphatemia","enrollment":161},{"nctId":"NCT01850641","phase":"PHASE3","title":"A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2013-04-29","conditions":"Hemodialysis, Hyperphosphatemia","enrollment":35},{"nctId":"NCT01521494","phase":"PHASE2","title":"PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2012-01-11","conditions":"Chronic Kidney Disease Requiring Hemodialysis","enrollment":183},{"nctId":"NCT01852682","phase":"PHASE3","title":"A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":"Peritoneal Dialysis, Hyperphosphatemia","enrollment":""},{"nctId":"NCT01324128","phase":"PHASE3","title":"A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients","status":"COMPLETED","sponsor":"Vifor Pharma","startDate":"2011-03","conditions":"Chronic Kidney Disease Requiring Chronic Dialysis","enrollment":1059},{"nctId":"NCT00824460","phase":"PHASE2","title":"Study of Phosphate Levels in Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Vifor Pharma","startDate":"2008-12","conditions":"Chronic Kidney Disease","enrollment":154},{"nctId":"NCT01464190","phase":"PHASE3","title":"A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients","status":"COMPLETED","sponsor":"Vifor Pharma","startDate":"2011-09","conditions":"Chronic Kidney Disease Requiring Chronic Dialysis","enrollment":659},{"nctId":"NCT01324752","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Losartan and PA21","status":"COMPLETED","sponsor":"Vifor Pharma","startDate":"2011-03","conditions":"Drug Interaction Potentiation","enrollment":36},{"nctId":"NCT01477424","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Warfarin and PA21","status":"COMPLETED","sponsor":"Vifor Pharma","startDate":"2011-11","conditions":"Drug Interaction Potentiation","enrollment":45},{"nctId":"NCT01477411","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Digoxin and PA21","status":"COMPLETED","sponsor":"Vifor Pharma","startDate":"2011-11","conditions":"Drug Interaction Potentiation","enrollment":42},{"nctId":"NCT01452906","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Omeprazole and PA21","status":"COMPLETED","sponsor":"Vifor Pharma","startDate":"2011-09","conditions":"Healthy","enrollment":45},{"nctId":"NCT01438359","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Furosemide and PA21","status":"COMPLETED","sponsor":"Vifor Pharma","startDate":"2011-07","conditions":"Healthy","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["sucroferric oxyhydroxide","Velphoro®"],"phase":"phase_3","status":"active","brandName":"PA21","genericName":"PA21","companyName":"Kissei Pharmaceutical Co., Ltd.","companyId":"kissei-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PA21 is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}